Clinical Trial

Clinical Autoinflammatory Disease Cohort

Study acronym: CAID
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Autoinflammatory diseases (AIDs) are a group of rare disorders caused by dysregulation of the innate immune system, characterized by recurrent fever, systemic inflammation, and involvement of specific organs. Diagnosis relies on a combination of clinical features, laboratory tests, genetic findings, and response to treatment. Still's disease is a representative type of AID, marked by high spiking fevers, polyarthritis, evanescent rash, and markedly elevated inflammatory markers. Among its complications, macrophage activation syndrome (MAS) is the most life-threatening, affecting approximately 10-15% of patients. MAS involves uncontrolled immune activation and systemic inflammation, and if left untreated, may result in a mortality rate exceeding 50%. This study aims to develop a standardized clinical dataset and diagnostic-treatment framework for AIDs based on their disease characteristics. After establishing a data collection template, eligible patients aged 18-75 years with AIDs will be enrolled. Clinical data will be collected to build a prospective follow-up cohort, focusing particularly on adult-onset Still's disease (AOSD), to explore the clinical features and pathogenesis of AIDs.
Trial Details
NCT Number NCT07126145
Lead Sponsor RenJi Hospital
Conditions Still Disease, Autoinflammatory Disease
Enrollment 1,000 participants
Start Date 2025-08
Primary Completion 2030-08 (estimated)
Study Completion 2035-08 (estimated)
Updated on ClinicalTrials.gov 2025-08-17